Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1080/week)
    • Manufacturing(512/week)
    • Technology(986/week)
    • Energy(432/week)
    • Other Manufacturing(340/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Lipoglycopeptide

May 26, 2020
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
May 11, 2020
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
Mar 23, 2020
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
Nov 25, 2019
New Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
Nov 14, 2019
FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance
Oct 08, 2019
Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11
Apr 03, 2019
Correvio Announces Xydalba(TM) (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019
Nov 06, 2018
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
Oct 12, 2018
The Menarini Group Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries
Oct 08, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018
Oct 01, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018
Sep 28, 2018
FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation
Apr 23, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
Apr 17, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
Apr 12, 2018
Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018
Mar 22, 2018
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
Mar 19, 2018
Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
Dec 11, 2017
Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference
Oct 31, 2017
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR(TM) Observational Patient Registry at 2017 CHEST Annual Meeting
Oct 30, 2017
Cardiome Announces Commercial Launch of Xydalba(TM) in Three New European Geographies
  •  
  • Page 1
  • ››

Latest News

Jul 24, 2025

Cincoze MXM GPU Computers: The AI Solutions for Manufacturing, Transportation, and Defense

Jul 24, 2025

Ryder Reports Second Quarter 2025 Results

Jul 24, 2025

Empire Petroleum Announces Extension of Previously Announced Rights Offering

Jul 24, 2025

Darling Ingredients Inc. Reports Second Quarter 2025 Results

Jul 24, 2025

Avolon Orders 90 Airbus Aircraft

Jul 24, 2025

Avolon Net Income up 36% to US$143 Million in Q2

Jul 24, 2025

Nidec Announces Preliminary Report on Performance Values (First Quarter of Fiscal Year 2025)

Jul 24, 2025

Nidec Announces the Disclosure of the Financial Results for the First Quarter of the Fiscal Year Ending March...

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia